Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic lymphocytic leukemia markets reached a value of US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.62% during 2024-2034.
The chronic lymphocytic leukemia market has been comprehensively analyzed in IMARC's new report titled "Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which the healthy white blood cells (lymphocytes) in the bone marrow start mutating or changing into cancerous cells. This occurs when an abnormally large number of lymphocytes proliferate, pushing out normal blood cells and making it harder for the body to fight infection. The disease is classified into B lymphocytes and T lymphocytes, depending on the type of cells affected. The common symptoms associated with this ailment include enlarged and painless lymph nodes, fatigue, fever, pain in the upper left portion of the abdomen, night sweats, unexplained weight loss, easy bruising, etc. Individuals suffering from CLL may also experience frequent infections, anemia, and enlargement of the spleen. Diagnosing this condition typically requires an evaluation of the patient’s medical history and clinical features. A complete blood count test that reveals a significant number of mature lymphocytes and smudge cells is often used to confirm the diagnosis. The healthcare provider may also perform several other examinations, including genomic testing, flow cytometry, imaging studies, bone marrow aspiration, biopsy, etc.
The increasing cases of genetic disorders that can cause multiple gene mutations in the DNA are primarily driving the chronic lymphocytic leukemia market. In addition to this, the expanding geriatric population, who are more vulnerable to CLL due to a greater frequency of comorbidities, reduced organ function, and functional impairment, is also bolstering the market growth. Furthermore, the widespread adoption of monoclonal antibodies in combination with chemotherapy for treating this ailment by binding specific proteins to tumor cells and activating a mechanism that destroys them is acting as another significant growth-inducing factor. Additionally, the escalating demand for allogeneic stem cell transplantation, which can improve chances of long-term remission and boost overall health, is also creating a positive outlook for the market. Apart from this, the emerging popularity of chimeric antigen receptor T-cell therapy among patients, since it uses the body’s immune cells to locate and destroy the tumor, is expected to drive the chronic lymphocytic leukemia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic lymphocytic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic lymphocytic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic lymphocytic leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic lymphocytic leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic lymphocytic leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic lymphocytic leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic lymphocytic leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic lymphocytic leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic lymphocytic leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by type across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic lymphocytic leukemia across the seven major markets?
What is the size of the chronic lymphocytic leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic lymphocytic leukemia?
What will be the growth rate of patients across the seven major markets?
Chronic Lymphocytic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic lymphocytic leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic lymphocytic leukemia market?
What are the key regulatory events related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by status related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by phase related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by route of administration related to the chronic lymphocytic leukemia market?
The chronic lymphocytic leukemia market has been comprehensively analyzed in IMARC's new report titled "Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which the healthy white blood cells (lymphocytes) in the bone marrow start mutating or changing into cancerous cells. This occurs when an abnormally large number of lymphocytes proliferate, pushing out normal blood cells and making it harder for the body to fight infection. The disease is classified into B lymphocytes and T lymphocytes, depending on the type of cells affected. The common symptoms associated with this ailment include enlarged and painless lymph nodes, fatigue, fever, pain in the upper left portion of the abdomen, night sweats, unexplained weight loss, easy bruising, etc. Individuals suffering from CLL may also experience frequent infections, anemia, and enlargement of the spleen. Diagnosing this condition typically requires an evaluation of the patient’s medical history and clinical features. A complete blood count test that reveals a significant number of mature lymphocytes and smudge cells is often used to confirm the diagnosis. The healthcare provider may also perform several other examinations, including genomic testing, flow cytometry, imaging studies, bone marrow aspiration, biopsy, etc.
The increasing cases of genetic disorders that can cause multiple gene mutations in the DNA are primarily driving the chronic lymphocytic leukemia market. In addition to this, the expanding geriatric population, who are more vulnerable to CLL due to a greater frequency of comorbidities, reduced organ function, and functional impairment, is also bolstering the market growth. Furthermore, the widespread adoption of monoclonal antibodies in combination with chemotherapy for treating this ailment by binding specific proteins to tumor cells and activating a mechanism that destroys them is acting as another significant growth-inducing factor. Additionally, the escalating demand for allogeneic stem cell transplantation, which can improve chances of long-term remission and boost overall health, is also creating a positive outlook for the market. Apart from this, the emerging popularity of chimeric antigen receptor T-cell therapy among patients, since it uses the body’s immune cells to locate and destroy the tumor, is expected to drive the chronic lymphocytic leukemia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic lymphocytic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic lymphocytic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic lymphocytic leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic lymphocytic leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic lymphocytic leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic lymphocytic leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic lymphocytic leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic lymphocytic leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic lymphocytic leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by type across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic lymphocytic leukemia across the seven major markets?
What is the size of the chronic lymphocytic leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic lymphocytic leukemia?
What will be the growth rate of patients across the seven major markets?
Chronic Lymphocytic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic lymphocytic leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic lymphocytic leukemia market?
What are the key regulatory events related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by status related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by phase related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by route of administration related to the chronic lymphocytic leukemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC LYMPHOCYTIC LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 CHRONIC LYMPHOCYTIC LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC LYMPHOCYTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC LYMPHOCYTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC LYMPHOCYTIC LEUKEMIA - UNMET NEEDS
10 CHRONIC LYMPHOCYTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC LYMPHOCYTIC LEUKEMIA - MARKETED PRODUCTS
11.1 List of Chronic Lymphocytic Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Treanda (Bendamustine) - Astellas Pharma GmbH
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Venclexta (Venetoclax) - AbbVie/Genentech
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Gazyva (Obinutuzumab) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Arzerra (Ofatumumab) - Genmab/Novartis
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Zydelig (Idelalisib) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC LYMPHOCYTIC LEUKEMIA - PIPELINE DRUGS
12.1 List of Chronic Lymphocytic Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Epcoritamab - Genmab
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Pirtobrutinib - Loxo Oncology
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Mosunetuzumab - Genentech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TGR-1202 - TG Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Cirmtuzumab - Oncternal Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC LYMPHOCYTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC LYMPHOCYTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC LYMPHOCYTIC LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Lymphocytic Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Chronic Lymphocytic Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Lymphocytic Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Lymphocytic Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Lymphocytic Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Lymphocytic Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Lymphocytic Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Lymphocytic Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
16 CHRONIC LYMPHOCYTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC LYMPHOCYTIC LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 CHRONIC LYMPHOCYTIC LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC LYMPHOCYTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC LYMPHOCYTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC LYMPHOCYTIC LEUKEMIA - UNMET NEEDS
10 CHRONIC LYMPHOCYTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC LYMPHOCYTIC LEUKEMIA - MARKETED PRODUCTS
11.1 List of Chronic Lymphocytic Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Treanda (Bendamustine) - Astellas Pharma GmbH
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Venclexta (Venetoclax) - AbbVie/Genentech
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Gazyva (Obinutuzumab) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Arzerra (Ofatumumab) - Genmab/Novartis
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Zydelig (Idelalisib) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC LYMPHOCYTIC LEUKEMIA - PIPELINE DRUGS
12.1 List of Chronic Lymphocytic Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Epcoritamab - Genmab
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Pirtobrutinib - Loxo Oncology
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Mosunetuzumab - Genentech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TGR-1202 - TG Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Cirmtuzumab - Oncternal Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC LYMPHOCYTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC LYMPHOCYTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC LYMPHOCYTIC LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Lymphocytic Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Chronic Lymphocytic Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Lymphocytic Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Lymphocytic Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Lymphocytic Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Lymphocytic Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Lymphocytic Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Lymphocytic Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
16 CHRONIC LYMPHOCYTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
